IUGNF - Imugene secures IND approval for first-in-class onCARlytics trial

(NewsDirect)

Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong takesProactive’s Elisha Newell through an Investigational New Drug (IND)approval for the company’s first-in-class onCARlytics clinicaltrial. The IND greenlight, granted by the US Food and DugAdministration, allows Imugene to start patient recruitment and dosingfor a Phase 1 study in adults with advanced or metastatic solidtumours. Chong sees the approval as a crucial step forward asclinicians and patients combat solid tumour cancers, which to datehave evaded treatment with CD19- targeting biologicaldrugs.

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

Jonathan@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.